Trial results

Semaglutide vs Sitagliptin

NCT05195944 on ClinicalTrials.gov · last registry update 2026-10-14

Closed to new participants; the 58 already enrolled are still being followed. Due to report December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in HbA1c level. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 26 October 2022 — 4 years so far. semaglutide is approved in the US, but not for diabetes and mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P4

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

University Health Network, Toronto

Sponsor type

Other

Enrollment

58

Started

2022-10-26

Primary completion

2026-12 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in HbA1c level

Conditions studied

Liver Transplant; Complications · Diabetes Mellitus · NASH - Nonalcoholic Steatohepatitis · NAFLD

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.